Skip to content

Multimodal magnetic resonance imaging changes in Prader-Willi syndrome before and after growth hormone treatment

Application of multimodal magnetic resonance imaging in pre - and post-treatment evaluation of recombinant human growth hormone in children with Prader-Willi syndrome

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046551
Enrollment
Unknown
Registered
2021-05-21
Start date
2021-05-18
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prader-Willi sydrome

Interventions

Prader-Willi sydrome group treated with rhGH:Treat with rhGH
Prader-Willi sydrome group treated without rhGH:Basic medicine

Sponsors

Cai Jinhua
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 16 Years

Inclusion criteria

Inclusion criteria: 1.Case group: Diagnosis must meet the diagnostic criteria of PWS; 2.Control group: A general physical examination is used to preliminarily determine that growth and development are within the normal rangeGriffiths Developmental Assessment Scale and Wechsler Intelligence Scale were within the normal range; No obvious organic disease was found in Conventional MR sequence screening.

Exclusion criteria

Exclusion criteria: 1. Case group: Sleep/sleep apnea, severe obesity, diabetes, tumor and mental illness still exist after treatment; 2. Control group: those who are significantly lagging behind in growth and development, routine MRI sequence screening revealed obvious organic diseases; 3. Subjects who are unwilling to continue participating in the study are raised during the inspection.

Design outcomes

Primary

MeasureTime frame
functional magenetic resonance imaging;

Countries

China

Contacts

Public ContactCai Jinhua

Children's Hospital of Chongqing Medical University

664662256@qq.com+86 23 63632756

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026